Pune, India -- (SBWire) -- 12/19/2018 --Multiple Sclerosis Treatment Market - Highlights
Multiple Sclerosis is a chronic, inflammatory, autoimmune disease that affects the central nervous system, specifically the communication between the brain and other parts of the body. The disease is characterized by damage to the insulating covers of nerve cells in the brain and spinal cord. There is no cure to multiple sclerosis.
GET PREMIUM SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/940
Multiple Sclerosis Treatment Market – Growth and Analysis
Its treatment focusses on speeding recovery from damages slowing the progression of diseases and management of symptoms of the disease. The global multiple sclerosis treatment market is expected to grow at a CAGR of 3.5% during forecasted period 2017-2023.
Global multiple sclerosis treatment market is expecting a steady growth in the near future. Increasing prevalence of muscle weakness related problems and increasing elderly population has driven the growth of the market.
The most preferred drug classes used for the treatment of multiple sclerosis include
Immunosuppressant (Zinbryta Lemtrada, Ocrelizumab, and Aubagio,)
Immunomodulators (Ampyra, Avonex, Gilneya, Betaseron, Tysabri, Rebif, Tecifidera, and Copaxone)
Multiple Sclerosis Treatment Market - Key Players
Teva Pharmaceuticals (Isreal)
Bayer Healthcare (Germany)
Biogen Idec (US)
Pfizer Inc. (US)
Sanofi Aventis (France)
Merck (US)
Novartis (Switzerland)
AbbVie (US)
Multiple Sclerosis Treatment Market – Regional Analysis
Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
The North America dominated the global multiple sclerosis treatment market with the U.S. holding the largest market share owing to numerous developments in the medical sector, and rising numbers of research institutes for better treatment of this diseases.
Additionally, the increasing number of hospitalization procedures due to high penetration of healthcare in the U.S. and Canada drives the multiple sclerosis market. In Europe, the market for multiple sclerosis is expected to exhibit positive growth during the forecast period.
Multiple Sclerosis Treatment Market - Industry Updates
August, 2016 Teva pharmaceutical Industries Ltd announced the completion of its acquisition of Allergan's generics business "Actavis Generics". Achieving synergies from the Actavis Generics acquisition and driving efficiency and effectiveness throughout our organization so as to extract the greatest benefit from the Actavis Generics acquisition is the key focus of the company.
May, 2014 Bayer AG acquired Merck & Co., Inc.'s non-prescription business to become the OTC leader in North America and Latin America & achieve top global positions in key OTC product categories.
OBTAIN COMPLETE 80 PAGES PREMIUM RESEARCH REPORT DETAILS ENABLED WITH RESPECTIVE 40+ TABLES AND FIGURES @ https://www.marketresearchfuture.com/reports/multiple-sclerosis-treatment-market-940
Major Points form TOC for Multiple Sclerosis Treatment Market Research Report – Forecast to 2023
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Global Multiple Sclerosis Treatment Market, By Type
Chapter 7. Global Multiple Sclerosis Treatment Market, By Treatment
Chapter 8 Global Multiple Sclerosis Treatment Market, By End User
Chapter 9. Global Multiple Sclerosis Treatment Market, By Region
Chapter 10 Company Landscape
Chapter 11 Company Profiles
Chapter 12 MRFR Conclusion
Chapter 13 Appendix
About Market Research Future
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Multiple Sclerosis Treatment Market Overview Along with Competitive Landscape, Regional Analysis, and Growth Opportunities Worldwide by 2023